(Total Views: 403)
Posted On: 11/20/2019 9:50:54 PM
Post# of 145249
I won’t even attempt to do the math, but even at 50% of revenues from HIV, cancer and NASH (pending approval trials and approval for cancer/NASH), CYDY would be a very valuable company.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)